课题基金 / 基金详情

STRUCTURE-ACTIVITY RELATIONSHIPS OF HUMAN ALPHA-CGRP

STRUCTURE-ACTIVITY RELATIONSHIPS OF HUMAN ALPHA-CGRP
人类 ALPHA-CGRP 的结构-活性关系
批准号:
2029000
负责人:
DEREK DAVID SMITH
金额:
$10.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-01-01 至 1998-12-31

项目摘要

项目成果

DEREK DAVID SMITH的其他基金

相似基金

相关文献

中文摘要
翻译
心血管疾病是美国人死亡的主要原因。 1989年有944,688名美国人死亡,占43%以上 在所有的死亡中。血压的降低与血压的降低有关 高血压患者的发病率和死亡率。降钙素 基因相关肽是存在的最强的扩血管多肽 当然。结构特征被认为是其生物学上的重要因素 活性是2位和7位之间的二硫键,α- 第8位和第22位之间的螺旋,第14位的残基。人类- α-CGRP(8-37)和[Tyr)O)-大鼠-α-CGRP(28-37)具有竞争性 对抗者。这项建议的长期目标是深入了解 H-α-CGRP的构象和形貌性质 对于在其受体上调节其生物学效应很重要。这个 一般的策略是(I)去除连续的末端氨基酸而不是 生物活性所需,(Ii)构象限制区域 有利于推测的生物活性构象的多肽和(Iii)获得 被确定为重要职位的结构-活动概况 生物活性。初步研究表明,没有氨基酸可以 从h-α-CGRP的C末端移除而不损失生物 活动。局部构象约束将施加在C- 末端部分(残基27-37)将D-氨基酸取代为 稳定假想的贝塔弯曲。全球约束将施加在 用Pen残基取代半胱氨酸的二硫键柔性 残留物。残基37的构效关系图,我们有 以前被证明对生物活动是必不可少的,将决定 在这个位置上,受体能耐受哪些官能团。这个 拮抗剂h-α-CGRP的C末端区域的重要性(8- 37),将按照上述战略(一)、(二)和(三)确定。 拮抗剂和拮抗剂C末端区域的相对重要性 我们将对天然多肽进行比较。一种新的综合策略,包括 将多肽片段缩合成MBHA树脂将用于 合成多肽类似物。完全受保护的片段将被 按照Kaiser的规程组装在一种肟基树脂上。生物学 类似物的活性和结合亲和力将在#年进行评估。 胰腺腺泡细胞、肠系膜动脉和心房。从以下方面获得的见解 这项提议将使设计有效的选择性激动剂和 H-α-CGRP拮抗剂将被证明是有用的药理学 用于表征新的公司受体的工具。此外,他们还 将成为设计治疗用具的优秀模型 降血压的药物。
英文摘要
Cardiovascular diseases are the principal cause of death in the United States today with 944,688 Americans dying in 1989 accounting for over 43% of all deaths. A reduction in blood pressure is associated with reduced morbidity and mortality of patients with high blood pressure. Calcitonin gene-related peptide is the most potent vasodilatory peptide occurring naturally. Structural features identified as important for its biological activity are the disulfide bridge between positions 2 and 7, the alpha- helix between positions 8 and 22, and the residue in position 14. human- alpha-CGRP (8-37) and [Tyr)O)-rat-alpha-CGRP (28-37) are competitive antagonists. The long term goal of this proposal is to gain insights into conformational and topographical properties of h-alpha-CGRP which are important for mediating its biological effects at its receptor. The general strategy is (i) to remove consecutive terminal amino acids not needed for biological activity, (ii) conformationally constrain regions of the peptide to favor putative bioactive conformations and (iii) obtain structure-activity profiles of positions identified as important for biological activity. Preliminary studies showed no amino acids can be removed from the C-terminus of h-alpha-CGRP without loosing biological activity. Local conformational constraints will be imposed on the C- terminal portion (residues 27-37) by substituting D-amino acids to stabilize putative beta-bends. Global constraints will be imposed on the flexibility of the disulfide bridge by substituting Pen residues for Cys residues. A structure-activity profile of residue 37, which we have previously shown to be essential for biological activity, will determine what functional groups the receptor will tolerate in this position. The importance of the C-terminal region of the antagonist, h-alpha-CGRP (8- 37), will be determined following strategies (i), (ii) and (iii) above. The relative importance of the C-terminal regions of the antagonist and the native peptide will be compared. A novel synthetic strategy involving the condensation of peptide fragments to a MBHA resin will be used to synthesize the peptide analogues. Fully protected fragments will be assembled on an oxime resin following Kaiser's protocols. Biological activity and binding affinity of the analogues will be assessed in pancreatic acinar cells, mesenteric artery and atria. Insights gained from this proposal will enable the design of potent selective agonists and antagonists of h-alpha-CGRP which will prove useful as pharmacological tools for the characterization of new CORP receptors. Furthermore, they will serve as excellent models for the design of therapeutically useful drugs to lower blood pressure.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1385/0-89603-399-6:75
发表时间: 1997
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Smith,DD, Hanly,AM]
通讯作者: Hanly,AM
Structure-activity studies on position 14 of human alpha-calcitonin gene-related peptide.
人α-降钙素基因相关肽14位的结构活性研究。
DOI: 10.1021/jm9608164
发表时间: 1997
期刊: Journal of medicinal chemistry.
影响因子: --
作者: [Li,J, Matsuura,JE, Waugh,DJ, Adrian,TE, Abel,PW, Manning,MC, Smith,DD]
通讯作者: Smith,DD
Functional calcitonin gene-related peptide subtype 2 receptors in porcine coronary arteries are identified as calcitonin gene-related peptide subtype 1 receptors by radioligand binding and reverse transcription-polymerase chain reaction.
通过放射性配体结合和逆转录聚合酶链反应,将猪冠状动脉中的功能性降钙素基因相关肽亚型2受体鉴定为降钙素基因相关肽亚型1受体。
DOI: --
发表时间: 2001
期刊: The Journal of pharmacology and experimental therapeutics.
影响因子: --
作者: [Rorabaugh,BR, Scofield,MA, Smith,DD, Jeffries,WB, Abel,PW]
通讯作者: Abel,PW
DOI: 10.1021/jm020507f
发表时间: 2003-06
期刊: Journal of medicinal chemistry
影响因子: 7.3
作者: [D. D. Smith-D.;S. Saha;Guoyong Fang;C. Schaffert;David J. J. Waugh-David-J.-J.-Waugh-2251816870;W. Zeng;G. Tóth;M. Hulce;Peter W. Abel]
通讯作者: D. D. Smith-D.;S. Saha;Guoyong Fang;C. Schaffert;David J. J. Waugh-David-J.-J.-Waugh-2251816870;W. Zeng;G. Tóth;M. Hulce;Peter W. Abel
INTERNET-DELIVERED OBESITY AND CARDIOMETABOLIC DISEASE PREVENTION
  • 批准号:
    8359729
  • 项目类别:
  • 资助金额:
    $13.69万
  • 财政年份:
    2011
  • 负责人:
    DEREK DAVID SMITH
  • 依托单位:
INTERNET-DELIVERED OBESITY AND CARDIOMETABOLIC DISEASE PREVENTION
  • 批准号:
    8167810
  • 项目类别:
  • 资助金额:
    $12.41万
  • 财政年份:
    2010
  • 负责人:
    DEREK DAVID SMITH
  • 依托单位:
COMMUNITY-BASED PARTICIPATORY RESEARCH
  • 批准号:
    7960339
  • 项目类别:
  • 资助金额:
    $32.08万
  • 财政年份:
    2009
  • 负责人:
    DEREK DAVID SMITH
  • 依托单位:
COMMUNITY-BASED PARTICIPATORY RESEARCH
  • 批准号:
    7720521
  • 项目类别:
  • 资助金额:
    $19.42万
  • 财政年份:
    2008
  • 负责人:
    DEREK DAVID SMITH
  • 依托单位:
海外基金